{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:58:05Z","timestamp":1794599885796,"version":"4.9.1"},"reference-count":50,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Inhibitors of the renin\u2013angiotensin\u2013aldosterone (RAAS) system are cornerstones of the management of patients with heart failure with reduced left ventricular ejection fraction (HFrEF). However, RAAS inhibitors may cause decline in renal function and\/or hyperkalaemia, particularly during initiation and titration, intercurrent illness and during worsening of heart failure. There is very little evidence from clinical trials to guide the management of renal dysfunction. The Renal Association and British Society for Heart Failure have collaborated to describe the interactions between heart failure, RAAS inhibitors and renal dysfunction and give clear guidance on the use of RAAS inhibitors in patients with HFrEF. During initiation and titration of RAAS inhibitors, testing renal function is mandatory; a decline in renal function of 30% or more can be acceptable. During intercurrent illness, there is no evidence that stopping RAAS inhibitor is beneficial, but if potassium rises above 6.0\u2009mmol\/L, or creatinine rises more than 30%, RAAS inhibitors should be temporarily withheld. In patients with fluid retention, high doses of diuretic are needed and a decline in renal function is not an indication to reduce diuretic dose: if the patient remains congested, more diuretics are required. If a patient is hypovolaemic, diuretics should be stopped or withheld temporarily. Towards end of life, consider stopping RAAS inhibitors. RAAS inhibition has no known prognostic benefit in heart failure with preserved ejection fraction. Efforts should be made to initiate, titrate and maintain patients with HFrEF on RAAS inhibitor treatment, whether during intercurrent illness or worsening heart failure.<\/jats:p>","DOI":"10.1136\/heartjnl-2018-314158","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T23:36:41Z","timestamp":1679701001000},"page":"904-910","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":91,"title":["Change in renal function associated with drug treatment in heart failure: national guidance"],"prefix":"10.1136","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8362-668X","authenticated-orcid":false,"given":"Andrew L","family":"Clark","sequence":"first","affiliation":[{"name":"Academic Cardiology, Hull York Medical School in the University of Hull, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R","family":"Kalra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Portsmouth Hospitals NHS Trust, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"University of Glasgow Institute of Cardiovascular and Medical Sciences, Glasgow, UK"},{"name":"Golden Jubilee National Hospital, Golden Jubilee National Hospital, Clydebank, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B","family":"Mark","sequence":"additional","affiliation":[{"name":"University of Glasgow Institute of Cardiovascular and Medical Sciences, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles RV","family":"Tomson","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Freeman Hospital, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"2025100705071434000_105.12.904.1","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2025100705071434000_105.12.904.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi696"},{"key":"2025100705071434000_105.12.904.3","unstructured":"National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. Clinical guideline [CG169]. London, 2013."},{"key":"2025100705071434000_105.12.904.4","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. Clinical guideline [CG182]. London, 2014."},{"key":"2025100705071434000_105.12.904.5","unstructured":"National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. NICE guideline [NG106]. London, 2018."},{"key":"2025100705071434000_105.12.904.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"2025100705071434000_105.12.904.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"2025100705071434000_105.12.904.8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","article-title":"Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data","volume":"10","author":"Beldhuis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2025100705071434000_105.12.904.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020676"},{"key":"2025100705071434000_105.12.904.10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn490"},{"key":"2025100705071434000_105.12.904.11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMra064398","article-title":"Normotensive ischemic acute renal failure","volume":"357","author":"Abuelo","year":"2007","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100705071434000_105.12.904.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00622.x"},{"key":"2025100705071434000_105.12.904.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2007.05.010"},{"key":"2025100705071434000_105.12.904.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.05.068"},{"key":"2025100705071434000_105.12.904.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.065"},{"key":"2025100705071434000_105.12.904.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.043"},{"key":"2025100705071434000_105.12.904.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.01.052"},{"key":"2025100705071434000_105.12.904.18","first-page":"60","article-title":"Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis","volume":"9","author":"Bagshaw","year":"2007","journal-title":"Crit Care Resusc"},{"key":"2025100705071434000_105.12.904.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2007.07.011"},{"key":"2025100705071434000_105.12.904.20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10557-016-6697-7","article-title":"Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure","volume":"30","author":"Pellicori","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025100705071434000_105.12.904.21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-1-1"},{"key":"2025100705071434000_105.12.904.22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrneph.2013.80","article-title":"Three feasible strategies to minimize kidney injury in \u2019incipient AKI'","volume":"9","author":"Perazella","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025100705071434000_105.12.904.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"2025100705071434000_105.12.904.24","doi-asserted-by":"crossref","unstructured":"McMurray JJV . Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med Overseas Ed 2014:371\u2013993.","DOI":"10.1056\/NEJMoa1409077"},{"key":"2025100705071434000_105.12.904.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.12.056"},{"key":"2025100705071434000_105.12.904.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.07.048"},{"key":"2025100705071434000_105.12.904.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.086"},{"key":"2025100705071434000_105.12.904.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013255"},{"key":"2025100705071434000_105.12.904.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6823.339"},{"key":"2025100705071434000_105.12.904.30","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)91194-9"},{"key":"2025100705071434000_105.12.904.31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256"},{"key":"2025100705071434000_105.12.904.32","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.13"},{"key":"2025100705071434000_105.12.904.33","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv094"},{"key":"2025100705071434000_105.12.904.34","doi-asserted-by":"crossref","unstructured":"Go AS , Hsu CY , Yang J , et al . Acute kidney injury and risk of heart failure and atherosclerotic events. Clin J Am Soc Nephrol 2018;13.doi:10.2215\/CJN.12591117","DOI":"10.2215\/CJN.12591117"},{"key":"2025100705071434000_105.12.904.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006497","article-title":"Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review","volume":"5","author":"Sawhney","year":"2015","journal-title":"BMJ Open"},{"key":"2025100705071434000_105.12.904.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012690","article-title":"Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study","volume":"6","author":"Mansfield","year":"2016","journal-title":"BMJ Open"},{"key":"2025100705071434000_105.12.904.37","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv023"},{"key":"2025100705071434000_105.12.904.38","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamainternmed.2018.4749","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury","volume":"178","author":"Brar","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025100705071434000_105.12.904.39","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfr123"},{"key":"2025100705071434000_105.12.904.40","doi-asserted-by":"crossref","unstructured":"Damman K , Valente MA , Voors AA , et al . Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014;35.doi:10.1093\/eurheartj\/eht386","DOI":"10.1093\/eurheartj\/eht386"},{"key":"2025100705071434000_105.12.904.41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413"},{"key":"2025100705071434000_105.12.904.42","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft110"},{"key":"2025100705071434000_105.12.904.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2011.08.009"},{"key":"2025100705071434000_105.12.904.44","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2016.06.423","article-title":"Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial","volume":"22","author":"Brisco","year":"2016","journal-title":"J Card Fail"},{"key":"2025100705071434000_105.12.904.45","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure","volume":"377","author":"Ellison","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100705071434000_105.12.904.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210357"},{"key":"2025100705071434000_105.12.904.47","unstructured":"Think Kidneys. \"Sick day\u201d guidance in patients at risk of Acute Kidney Injury: a Position Statement from the Think Kidneys Board. https:\/\/www.thinkkidneys.nhs.uk\/aki\/wp-content\/uploads\/sites\/2\/2018\/01\/Think-Kidneys-Sick-Day-Guidance-2018.pdf."},{"key":"2025100705071434000_105.12.904.48","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update. 2016."},{"key":"2025100705071434000_105.12.904.49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018153","article-title":"Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin-angiotensin system blockers: a UK primary care cohort study","volume":"7","author":"Sinnott","year":"2017","journal-title":"BMJ Open"},{"key":"2025100705071434000_105.12.904.50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2018-314158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:14:40Z","timestamp":1759839280000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2018-314158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,5,22]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1136\/heartjnl-2018-314158"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2018-314158","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]}}}